Grifols (GIKLY) Net Cash Flow (2010 - 2020)
Grifols (GIKLY) reported Net Cash Flow of -$130.2 million for Q1 2020, up 75.96% on a YoY basis from -$74.0 million in Q2 2019, and up 59.92% quarter-over-quarter from -$324.9 million in Q4 2019.
Grifols (GIKLY) Net Cash Flow (2010 - 2020) Analysis & Trends
Grifols has reported Net Cash Flow for 10 years, with the latest figure at -$130.2 million in Q1 2020.
- For the quarter ending Q1 2020, Net Cash Flow rose 75.96% year-over-year to -$130.2 million; the trailing twelve-month figure through Dec 2025 stood at $0.0 (changed 0.0% YoY), and the FY2025 full-year result was -$71.0 million, down 115.49% from the prior year.
- Net Cash Flow for Q1 2020 stood at -$130.2 million, up from -$324.9 million in the prior quarter.
- The five-year high for Net Cash Flow was $4.9 billion in Q4 2017, with the low at -$604.2 million in Q3 2016.
- Historically, Net Cash Flow has averaged $751.8 million across 5 years, with a median of -$72.0 million in 2016.
- Annual changes were most pronounced in 2016 — Net Cash Flow plunged 322.73% — and 2017, when it jumped 6845.21%.
- Grifols' Net Cash Flow stood at -$72.0 million in 2016, then jumped by 6845.21% to $4.9 billion in 2017, then slumped by 72.95% to $1.3 billion in 2018, then plunged by 124.72% to -$324.9 million in 2019, then soared by 59.92% to -$130.2 million in 2020.
- The last three Net Cash Flow figures came in at -$130.2 million (Q1 2020), -$324.9 million (Q4 2019), and -$541.8 million (Q1 2019), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 210.32 Mn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | -2.05 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 2.00 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 4.17 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -9.27 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 2.91 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 75.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 544.00 Mn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -587.00 Mn |
| 10 | Grifols | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | -130.24 Mn |
| Mar 31, 2020 | -130.24 Mn |
| Dec 31, 2019 | -324.92 Mn |
| Dec 31, 2019 | -324.92 Mn |
| Mar 31, 2019 | -541.80 Mn |
| Mar 31, 2019 | -541.80 Mn |
| Dec 31, 2018 | 1.31 Bn |
| Dec 31, 2018 | 1.31 Bn |
| Jun 30, 2018 | -530.10 Mn |
| Jun 30, 2018 | -530.10 Mn |
| Mar 31, 2018 | 249.20 Mn |
| Mar 31, 2018 | 249.20 Mn |
| Dec 31, 2017 | 4.86 Bn |
| Dec 31, 2017 | 4.86 Bn |
| Jun 30, 2017 | 247.39 Mn |
| Jun 30, 2017 | 247.39 Mn |
| Mar 31, 2017 | 3.80 Bn |
| Mar 31, 2017 | 3.80 Bn |
| Dec 31, 2016 | -72.03 Mn |
| Dec 31, 2016 | -72.03 Mn |